King's College London Enterprises

King's College London Enterprises is the commercialization and technology transfer arm of King's College London. It manages the university's intellectual property portfolio, facilitates licensing agreements with industry partners, and supports the creation of spin-out companies across various sectors, with a heavy emphasis on life sciences, healthcare, and biotechnology. The organization bridges the gap between academic research and commercial application, overseeing a diverse pipeline of innovations ranging from novel therapeutics and medical devices to digital health solutions. Notable successes include the formation of high-profile companies like Quell Therapeutics and AviadoBio, as well as the acquisition of spin-outs like ReViral by Pfizer. By leveraging the university's world-class research base, the enterprise accelerates the delivery of life-changing technologies to the global market.